Patents Assigned to Boehringer Ingelheim International GmbH
  • Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
    Patent number: 9932324
    Abstract: The present invention relates to compounds of formula (I), or the tautomers or pharmacologically acceptable acid addition salts thereof, wherein R1, R2, R3, R4, X, and Z have one of the meanings as defined in the specification, to the use of compounds of formula (I) as a medicament, to pharmaceutical composition comprising at least one compound of formula (I), as well as to medicament combinations containing one or more compounds of formula (I).
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: April 3, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Kley, Joerg P. Hehn, Armin Heckel
  • Anti CD37 antibodies
    Patent number: 9932399
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 3, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann
  • Pyridinyl derivatives, pharmaceutical compositions and uses thereof
    Patent number: 9926292
    Abstract: The invention relates to new pyridinyl derivatives of the formula wherein R1 and A are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Blum, Cédrickx Godbout, Joerg P. Hehn, Stefan Peters
  • N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof
    Patent number: 9926308
    Abstract: Compounds of formula I wherein R1, LP, n, HetAr1, and HetAr2 are as defined herein, and salts thereof, pharmaceutical compositions containing these compounds, and methods for treating diseases or conditions which are mediated by activating the G-protein-coupled receptor GPR119, such as diabetes, dislipidemia, or obesity, by administering to a patient in need thereof these compounds or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bernd Nosse, Matthias Eckhardt, Frank Himmelsbach, Elke Langkopf, Neil J. Ashweek, Nicole Harriott
  • Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
    Patent number: 9925174
    Abstract: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Ulrich Brauns
  • Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
    Patent number: 9920035
    Abstract: The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, and the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: March 20, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Sara Frattini, Dieter Hamprecht, Joerg Kley
  • Heteroaryl Syk inhibitors
    Patent number: 9914735
    Abstract: The invention relates to new substituted heteroaryls of formula (1), wherein A is selected from the group consisting of N and CH, D is CH, E is selected from the group consisting of C and N, T is C, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R1, M and R3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: March 13, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Georg Dahmann, Matthias Hoffmann, Jasna Klicic, David James Lamb, Clive McCarthy, Spencer Charles R. Napier, Karen Parrish, John Scott, Jennifer L. Swantek Fitzgerald, Edward Walker
  • Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
    Patent number: 9907756
    Abstract: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: March 6, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Roman Messerschmid, Rudolf Binder, Thomas Bock, Werner Brox
  • Aldosterone synthase inhibitors
    Patent number: 9890171
    Abstract: The present invention relates to compounds of the formulas (IA) and (IB) and pharmaceutically acceptable salts thereof, wherein A and R1-R6, are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: February 13, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Zhidong Chen, Derek Cogan, Xin Guo, Daniel Richard Marshall, Kenneth Michael Meyers, Yunlong Zhang
  • N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides
    Patent number: 9884854
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 6, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Friederike Lessel, Janet Rachel Nicholson, Anton Pekcec, Stefan Scheuerer
  • Substituted spirocycles
    Patent number: 9879026
    Abstract: This invention relates to a compound of formula I wherein A and Cy have one of the meanings as indicated in the specification and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: January 30, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Viktor Vintonyak, Matthias Grauert, Marc Grundl, Alexander Pautsch
  • Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
    Patent number: 9873714
    Abstract: The present invention relates to processes for preparing a glucopyranosyl-substituted benzyl-benzene derivative of general formula III, wherein R1 is defined according to claim 1.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: January 23, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Weber, Tobias Fiedler, Christian Filser, Rainer Hamm, Simone Orlich, Matthias Post, Svenja Renner, Xiao-Jun Wang, Thomas Wirth
  • Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
    Patent number: 9867831
    Abstract: The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Quizartinib or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: January 16, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Tillmann Taube, Dorothea Rudolph
  • METHODS OF TREATING DISEASES
    Publication number: 20180009887
    Abstract: This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-IL-23A antibodies.
    Type: Application
    Filed: August 25, 2017
    Publication date: January 11, 2018
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Kirsten Arndt-Schmitz, Alix Berton, Michael Chadham Nivens, Karsten Quast, Marco Schlepuetz, Sudha Visvanathan
  • Anti-BAFF antibodies
    Patent number: 9840543
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: December 12, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith Canada, Mlchael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John James Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • Nebulizer
    Patent number: 9827384
    Abstract: A nebulizer is proposed which comprises a replaceable container containing fluid, a housing part detachable from the nebulizer for replacing the container, and an operation counter inseparable from the housing part as depicted in exemplary FIG. 10. The operation counter comprises a lead screw and an associated rider both supported by the housing part.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: November 28, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Holger Holakovsky, Ralf Thoemmes, Marc Rohrschneider, Florian Witte, Kevin Peter Deane, Douglas Ivan Jennings
  • Filter system for use in medical devices
    Patent number: 9827382
    Abstract: A medical hand-held device, in particular an atomizer, for dispensing a liquid pharmaceutical preparation from a container with a discharge nozzle for the pharmaceutical preparation and located upstream from the discharge nozzle there is a multiple-stage filter system.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 28, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Hausmann, Steffen Schuy, Joachim Eicher, Johannes Geser, Martin Meisenheimer, Florian Witte
  • Pyrazole compounds as BTK inhibitors
    Patent number: 9828364
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy, and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 28, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Bentzien, Angela Kay Berry, Todd Bosanac, Michael Jason Burke, Darren Todd Disalvo, Can Mao, Wang Mao, Yue Shen
  • Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
    Patent number: 9815782
    Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: November 14, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
  • Polymorphs
    Patent number: 9815837
    Abstract: The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: November 14, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Sieger, Dirk Kemmer, Peter Kohlbauer, Thomas Nicola, Martin Renz